Ozempic (semaglutide) is one of several injectable medications that activate GLP-1 receptors to support weight management, but alternatives with different mechanisms exist
Synaptic plasticity is impaired in rats with a low glutathione content
Dont Overlook Electrolytes Dehydration is one of the most common side effects of GLP-1 medications, especially early in treatment
Demand for GLP-1 therapies is likely to increase with the availability of oral forms, as many patients are needle-averse and would welcome a non-invasive alternative, Dr
Novo Nordisk and Eli Lilly have positioned themselves at the forefront of this space with their blockbuster GLP-1 receptor agonist drugs Ozempic, Wegovy, and Rybelsus from Novo Nordisk, and Mounjaro and Zepbound from Lilly targeting both Type 2 diabetes and obesity
J Anat (2002) 200(6):58197